-
公开(公告)号：US12115215B2
公开(公告)日：2024-10-15
申请号：US18451461
申请日：2023-08-17
发明人： Yi-Pin Lin , Kaspars Tars
CPC分类号： A61K39/0225 , A61P31/04 , A61K2039/5258 , A61K2039/55566
摘要： Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids of SEQ ID NO:1 and one or more adjuvants. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition.
-
公开(公告)号：US20240101701A1
公开(公告)日：2024-03-28
申请号：US18546394
申请日：2022-02-17
发明人： Leonid CHERKASSKY , Richard KOYA , Kunle ODUNSI , Ben K. SEON
IPC分类号： C07K16/28 , A61K39/00 , C07K14/705 , C07K14/725 , C12N5/0783
CPC分类号： C07K16/2896 , A61K39/4611 , A61K39/4631 , A61K39/464429 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C12N5/0636 , A61K2239/29 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N2510/00
摘要： Antibody derivatives are provided as binding partners. The binding partners bind to a one or a combination of antigens that include antigens present CD24, CD105 (endoglin), CD79 Beta (CD79b), and an antigen present in a CD3 T cell co-receptor. The antibody derivatives include single chain variable fragments (scFvs), Bi-specific T-cell engagers (BiTEs). Also provided are modified cells that express the binding partners, modified cells that secrete the binding partners, expression vectors that encode the binding partners, and methods of using the binding partners for treatment of a variety of cancers, autoimmune diseases, and modification of immune responses mounted to transplanted organs.
-
公开(公告)号：US20240009276A1
公开(公告)日：2024-01-11
申请号：US18249816
申请日：2021-10-22
发明人： Pawel KALINSKI
IPC分类号： A61K38/21 , A61K31/713 , A61P37/04 , A61P31/14 , A61K38/19
CPC分类号： A61K38/212 , A61K31/713 , A61K38/217 , A61P37/04 , A61P31/14 , A61K38/191
摘要： Provided are methods for prophylaxis and therapy for viral infections. The methods can facilitate a synergistic anti-viral effect. The method involves administering a combination of agents to an individual in need thereof. The combinations of agents are selected from interferons (IFNs), Toll-Like Receptor (TLR) ligands, polyinosinic:polycytidylic acid, rintatolimod, tumor necrosis factor alpha (TNF-a) or an inducer thereof, and nuclear factor kappa B (NF-xB) or an inducer or activator thereof.
-
公开(公告)号：US11767303B2
公开(公告)日：2023-09-26
申请号：US17384051
申请日：2021-07-23
申请人： Health Research, Inc. , Arizona Board of Regents on Behalf of the University of Arizona , Board of Regents, The University of Texas System
发明人： Hongmin Li , Zhong Li , Jia Zhou , Jimin Xu , Qing-Yu Zhang
IPC分类号： A61K31/5375 , C07D265/30 , C07C233/75 , C07D211/46 , A61P31/14 , C07D409/12 , C07D213/75 , C07D333/54
CPC分类号： C07D265/30 , A61P31/14 , C07C233/75 , C07D211/46 , C07D213/75 , C07D333/54 , C07D409/12
摘要： The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected with a virus with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the virus comprises a flavivirus. Also disclosed is a method of treating and/or preventing a flavivirus infection and/or a condition resulting from a flavivirus infection including administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof under conditions effective to treat and/or prevent a flavivirus infection and/or a condition resulting from a flavivirus infection.
-
5.发明公开公开(公告)号：US20230173301A1
公开(公告)日：2023-06-08
申请号：US18162995
申请日：2023-02-01
发明人： Gal Shafirstein , David Bellnier
CPC分类号： A61N5/062 , A61N5/0601 , G01K7/36 , A61N2005/0612 , A61N2005/0628 , A61N2005/063
摘要： The present disclosure provides a method and a system for treating a tissue using photodynamic therapy (PDT). A photosensitizer is administered to the tissue and one or more optical fibers are placed in the tissue. A treatment light is applied to the tissue by way of the one or more optical fibers. A temperature of the tissue is measured during application of the treatment light, and a fluence rate of the treatment light is modified based on the temperature of the tissue. For example, the fluence rate may be modified to be lower if the temperature of the tissue is higher than a predetermined threshold.
-
公开(公告)号：US20220395494A1
公开(公告)日：2022-12-15
申请号：US17773838
申请日：2020-11-05
发明人： Scott I. ABRAMS , Sean H. COLLIGAN
IPC分类号： A61K31/47 , A61P35/00 , A61K31/4353
摘要： Provided are methods for treatment of cancer. The method comprises administering to an individual who has cancer a combination of treatment to reduce MDSC burden and immune therapy. For example, an individual may be administered brequinar and an immune checkpoint inhibitor. This disclosure provides a method for redirecting early myeloid precursors away from generating MDSCs thereby reducing MDSC burden.
-
公开(公告)号：US11491123B2
公开(公告)日：2022-11-08
申请号：US16312316
申请日：2017-06-23
申请人： HEALTH RESEARCH, INC. , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： Hongmin Li , Laura D. Kramer , Zhong Li , Ruili Huang , Menghang Xia
IPC分类号： A61K31/167 , A61K31/426 , A61K31/609 , A61K31/352 , A61K31/409 , A61K31/5415 , A61P31/14 , C07C235/64
摘要： Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin B, methylene blue. Contacting one or more cells that have been infected with a flavivirus may include administering the compound to a mammal, a human, or other subject. The flavivirus may be Dengue virus serotype 1, Dengue virus serotype 2, Dengue virus serotype 3, Dengue virus serotype 4, yellow fever virus, West Nile virus, Zika virus, Japanese encephalitis virus, tick-born encephalitis virus, Powassan virus, St. Louis encephalitis virus, or other flavivirus.
-
公开(公告)号：US20220280627A1
公开(公告)日：2022-09-08
申请号：US17705461
申请日：2022-03-28
发明人： Yi-Pin LIN
摘要： Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition
-
公开(公告)号：US20220249531A1
公开(公告)日：2022-08-11
申请号：US17628894
申请日：2020-07-27
发明人： Andrei BAKIN , Justin ZONNEVILLE
IPC分类号： A61K31/7072 , A61K31/513 , A61K31/5025 , A61K31/502 , A61P35/00
摘要： Provided are methods and formulations for the treatment of p53-deficient cancers using a combinational drug strategy which enhances DNA damage in p53 deficient cells while not allowing cells to escape cell death by activation of p53-p21 signaling. Wild-type p53 carriers, on the other hand, respond with activation of p53-p21 signaling and cell-cycle arrest, thereby escaping cell death. The methods involve administering to an individual in need of treatment a combination of one or more poly (ADP ribose) polymerase inhibitors (PARPi) and one or more deoxyuridine analogs. Pharmaceutical formulations comprising PARPi and dU analogs are also provided.
-
公开(公告)号：US20220218722A1
公开(公告)日：2022-07-14
申请号：US17606998
申请日：2020-04-27
IPC分类号： A61K31/585 , A61K31/167 , A61K31/277 , A61K31/4166 , A61K31/4439 , A61K31/4155 , A61K31/58 , A61K31/496 , A61K49/00 , C07J43/00
摘要： Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and/or hyperplastic cells and/or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and/or hyperplastic cell growth and/or molecular imaging of malignant cells and/or hyperplastic cells and/or inducing degradation of a target protein. Also provided are compositions.
-
-
-
-
-
-
-
-
-
搜索结果
199 条记录 (耗时 0.029 秒)
